Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - cisplatin - concentrate for solution for infusion - 0,5mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - cisplatin - concentrate for solution for infusion - 0,5mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoclopramide hydrochloride monohydrate 5 mg/ml;   - solution for injection - 5 mg/ml - active: metoclopramide hydrochloride monohydrate 5 mg/ml   excipient: hydrochloric acid sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoclopramide hydrochloride monohydrate 5 mg/ml;   - solution for injection - 5 mg/ml - active: metoclopramide hydrochloride monohydrate 5 mg/ml   excipient: hydrochloric acid sodium chloride water for injection

United States - English - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal i

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium hydroxide - cisplatin intas may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cetuximab 5 mg/ml;  ;   - solution for infusion - 5 mg/ml - active: cetuximab 5 mg/ml     excipient: citric acid monohydrate glycine polysorbate 80 sodium chloride sodium hydroxide water for injection - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer · in combination with infusional 5-fluorouracil/folinic acid plus irinotecan · in combination with irinotecan in patients who are refractory to first-line chemotherapy · in first-line in combination with folfox · as a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy. (see clinical trials)

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - oxaliplatin 5 mg/ml;  ;  ; oxaliplatin 5 mg/ml - concentrate for infusion - 5 mg/ml - active: oxaliplatin 5 mg/ml     excipient: lactose monohydrate water for injection active: oxaliplatin 5 mg/ml excipient: nitrogen water for injection - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - cisplatin - concentrate for soln for inf - 1 mg/ml - platinum compounds

Ireland - English - HPRA (Health Products Regulatory Authority)

caduceus pharma ltd - cisplatin - concentrate for soln for inf - 1 mg/ml - platinum compounds